Literature DB >> 7962284

Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism.

P Moghetti1, R Castello, C M Magnani, F Tosi, C Negri, D Armanini, G Bellotti, M Muggeo.   

Abstract

Hyperactivity of 5 alpha-reductase in the skin is considered a major mechanism of excessive hair growth in hirsute women with normal levels of serum androgens (idiopathic hirsutism). Preventing the conversion of testosterone to dihydrotestosterone by inhibiting 5 alpha-reductase activity could thus be the most rational and effective treatment in this condition. The present study evaluated the effects of the oral administration of finasteride (5 mg once daily) for 6 months in 17 young women with idiopathic hirsutism, 5 of whom were also given an oral contraceptive. The degree of hirsutism (graded by a modified Ferriman-Gallwey score), serum sex hormone levels, and serum and urinary 5 alpha-metabolism steroid profiles were determined basally and periodically during the treatment period. The modified Ferriman-Gallwey score showed a remarkable reduction after 6 months of finasteride treatment (5.9 +/- 0.6 vs. 11.7 +/- 1.3; P < 0.01). Serum 5 alpha-dihydrotestosterone and 3 alpha-androstanediol glucuronide levels were decreased, and urinary C19 and C21 5 beta/5 alpha metabolite ratios were increased compared with pretreatment values. No significant adverse effect was reported. In women treated with finasteride and oral contraceptive, clinical efficacy was slightly more pronounced. In conclusion, the 5 alpha-reductase inhibitor finasteride is well tolerated and seems to be a useful tool in the treatment of idiopathic hirsutism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962284     DOI: 10.1210/jcem.79.4.7962284

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 2.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

3.  Finasteride. Does it affect spermatogenesis and pregnancy?

Authors:  M Pole; G Koren
Journal:  Can Fam Physician       Date:  2001-12       Impact factor: 3.275

Review 4.  Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

Authors:  Jason M Hirshburg; Petra A Kelsey; Chelsea A Therrien; A Carlo Gavino; Jason S Reichenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

5.  Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism.

Authors:  Y Sahin; F Bayram; F Keleştimur; I Müderris
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

6.  Effect of finasteride in idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; S Di Marco; F Mantero
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

7.  Adverse Effects with Finasteride 5 mg/day for Patterned Hair Loss in Premenopausal Women.

Authors:  Rui Oliveira-Soares; Marisa C André; Miguel Peres-Correia
Journal:  Int J Trichology       Date:  2018 Jan-Feb

Review 8.  Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism.

Authors:  Decio Armanini; Marco Boscaro; Luciana Bordin; Chiara Sabbadin
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

9.  Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women.

Authors:  Gadah Albasher; May Bin-Jumah; Saleh Alfarraj; Fatimah Al-Otibi; Nouf K Al-Sultan; Saud Alarifi; Saad Alkahtani; Nahed S Alharthi; Wedad S Al-Qahtani
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.